Teva and Alvotech have announced receipt of the US FDA approval to Selarsdi injection for use as an interchangeable with ...

Pharma major Dr Reddy’s Laboratories Ltd’s consolidated net profit increased 21% in the fourth quarter ended March 31, 2025 ...

The updated recommendations also provide guidance on antirheumatic drug use through lactation and in male patients trying to ...

Two biosimilars developed under the Teva - Alvotech partnership have been granted FDA approval with interchangeability, including SELARSDI. In February 2024, the FDA approved SIMLANDI ® ...

Operating profit / (loss): Operating profit was $10.6 million for the three months ended 31 March 2025, compared to ($48.4) ...

Alvotech and Teva noted that they have three additional biosimilar candidates under review by the US regulator: a proposed biosimilar for Simponi (golimumab) and Simponi Aria (golimumab), AVT05 ...

Biosimilar partnerships included Daratumumab, ustekinumab, and golimumab, with a Denosumab filing accepted by the U.S. FDA. NRT integration advanced, with the UK completed and Nordics underway.

The partners also announced filing acceptance of U.S. Biologics License Applications (BLAs) for AVT05, a proposed biosimilar to Simponi® and Simponi Aria® (golimumab) and a BLA for AVT06 ...

Golimumab (Simponi; Centocor), the first once-monthly, self-injectable TNF-specific mAb, was recently launched for RA, psoriatic arthritis and ankylosing spondylitis. Golimumab has the potential ...

He noted that in the longer term, J&J 's sales of Simponi Aria (golimumab) continue to grow in rheumatoid arthritis. The company has noted that s J&J has also filed sirukumab in the US and EU ...